Document Detail


Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis.
MedLine Citation:
PMID:  17565924     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An enhanced understanding of the immunopathology of rheumatoid arthritis (RA) has led to the development of novel therapies that target specific events occurring in the immune cascade that underlies the disease. In December 2005, abatacept became the first therapy to be approved by the US Food and Drug Administration for the treatment of adult patients with moderately to severely active RA who have exhibited an inadequate response to traditional disease-modifying antirheumatic drugs or tumor necrosis factor antagonists. This article summarizes the characteristics and clinical profile of abatacept. Abatacept is a fully human soluble recombinant fusion protein that acts by binding to CD80/CD86 on antigen-presenting cells and inhibiting interaction with CD28 on T cells, thus preventing one of the co-stimulatory signals needed for full T-cell activation. It is indicated for reducing signs and symptoms of the disorder, inducing a major clinical response, slowing the progression of structural damage, and improving physical function in this patient population. Data on abatacept compiled to date demonstrate significant efficacy, combined with a consistent safety profile and tolerability, in a wide range of patients with RA, including those with an inadequate response to methotrexate or to tumor necrosis factor antagonists.
Authors:
Lisa Lundquist
Related Documents :
18199544 - The adenocarcinoma-associated antigen, agr2, promotes tumor growth, cell migration, and...
2686854 - Activation of the k-ras oncogene in liver tumors of hudson river tomcod.
15833854 - Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia indu...
12226664 - Loss of the lkb1 tumour suppressor provokes intestinal polyposis but resistance to tran...
24058864 - Depletion of the er chaperone enpl-1 sensitizes c. elegans to the anticancer drug cispl...
8516614 - Molecular basis of tumor progression: mechanisms of organ-specific tumor metastasis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Advances in therapy     Volume:  24     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:    2007 Mar-Apr
Date Detail:
Created Date:  2007-06-13     Completed Date:  2007-07-31     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  333-45     Citation Subset:  T    
Affiliation:
Mercer University College of Pharmacy and Health Science, Atlanta, GA 30341, USA. lundquist_lm@mercer.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antigens, CD28 / metabolism
Antigens, CD80 / metabolism
Antigens, CD86 / metabolism
Antirheumatic Agents / adverse effects,  pharmacokinetics,  therapeutic use*
Arthritis, Rheumatoid / drug therapy*,  immunology
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Humans
Immunoconjugates / adverse effects,  pharmacokinetics,  therapeutic use*
Randomized Controlled Trials as Topic
T-Lymphocytes / metabolism
Chemical
Reg. No./Substance:
0/Antigens, CD28; 0/Antigens, CD80; 0/Antigens, CD86; 0/Antirheumatic Agents; 0/Immunoconjugates; 7D0YB67S97/abatacept

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of hyperbaric oxygen therapy on distraction osteogenesis.
Next Document:  Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood press...